PMID- 31801393
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Apr
TI  - Real-world comparison of hospitalization costs for heart failure in type 2 
      diabetes mellitus patients with established cardiovascular disease treated with 
      canagliflozin versus other antihyperglycemic agents.
PG  - 401-406
LID - 10.1080/13696998.2019.1693384 [doi]
AB  - Aims: This real-world study compared hospitalization for heart failure (HHF) 
      costs and all-cause healthcare costs in patients with type 2 diabetes mellitus 
      (T2DM) and established cardiovascular disease treated with the sodium glucose 
      co-transporter 2 inhibitor (SGLT2i) canagliflozin and non-SGLT2i 
      antihyperglycemic agents (AHAs).Materials and methods: Propensity score-matched 
      cohorts from a retrospective observational study (OBSERVE-4D) using the Truven 
      MarketScan Commercial Claims and Encounters and Optum Clinformatics databases 
      were analyzed. HHF and all-cause healthcare costs per-patient-per-month (PPPM) 
      were compared for patients initiated on canagliflozin and non-SGLT2i AHAs in the 
      on-treatment analysis.Results: Baseline characteristics were well balanced 
      between matched cohorts that included new users of canagliflozin or non-SGLT2i 
      AHAs in the Truven (13,954 and 45,101, respectively) and Optum (11,490 and 
      53,360, respectively) databases. The mean (95% CI) PPPM cost of HHF was lower for 
      canagliflozin than for non-SGLT2i AHAs in analyses of both the Truven ($21.31 
      [$21.25, $21.37]) and Optum ($30.43 [$30.41, $30.45]) databases. The mean (95% 
      CI) PPPM all-cause healthcare cost was also lower for canagliflozin than for 
      non-SGLT2i AHAs in analyses of both the Truven ($321 [$280, $361]) and Optum 
      ($449 [$402, $495]) databases.Limitations: This study is subject to the 
      limitations inherent to observational research including potential for coding 
      errors and biases and unobserved confounding. Because all patients were in 
      commercially administered health plans, these findings cannot be easily 
      generalized to uninsured or Medicaid populations. Patient costs were evaluated up 
      to and including their first HHF event. Post-discharge costs such as the costs of 
      subsequent rehospitalizations were not included in this analysis.Conclusions: For 
      patients with T2DM and established cardiovascular disease in this real-world 
      study, treatment with canagliflozin was associated with lower HHF costs and 
      all-cause healthcare costs compared with treatment with non-SGLT2i AHAs.
FAU - Chen, Yen-Wen
AU  - Chen YW
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
FAU - Voelker, Jennifer
AU  - Voelker J
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
FAU - Tunceli, Ozgur
AU  - Tunceli O
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
FAU - Pericone, Christopher D
AU  - Pericone CD
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
FAU - Bookhart, Brahim
AU  - Bookhart B
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
FAU - Durkin, Michael
AU  - Durkin M
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20191204
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Canagliflozin/*administration & dosage
MH  - Cardiovascular Diseases/*drug therapy
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - *Health Care Costs
MH  - Heart Failure/*economics
MH  - Hospitalization/*economics
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Sodium-Glucose Transporter 2 Inhibitors/*administration & dosage
MH  - Young Adult
OTO - NOTNLM
OT  - I00
OT  - I10
OT  - antihyperglycemic agents
OT  - canagliflozin
OT  - cardiovascular disease
OT  - cost
OT  - hospitalization for heart failure
OT  - type 2 diabetes
EDAT- 2019/12/06 06:00
MHDA- 2021/01/22 06:00
CRDT- 2019/12/06 06:00
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2019/12/06 06:00 [entrez]
AID - 10.1080/13696998.2019.1693384 [doi]
PST - ppublish
SO  - J Med Econ. 2020 Apr;23(4):401-406. doi: 10.1080/13696998.2019.1693384. Epub 2019 
      Dec 4.